

IN THE CLAIMS:

Please cancel Claims 9, 10, 17, 18, 20, 22, 28, 33, 36, 37, 38, 39 and 41 without prejudice.

Please amend Claims 7, 8, 11, 12, 19, 21, 27, 34 and 40 as follows:

B<sup>1</sup>  
7. (Amended) The OMP106 polypeptide of claim 1, which specifically binds an antibody that specifically binds the sequence of SEQ ID NO. 1.

8. (Amended) The OMP106 polypeptide of claim 1, which specifically binds an antibody that specifically binds the sequence of SEQ ID NO. 11.

B<sup>2</sup>  
11. (Amended) The OMP106 polypeptide of claim 1, which comprises the sequence of SEQ ID NO. 1.

12. (Amended) The OMP106 polypeptide of claim 11, which additionally comprises the sequence of SEQ ID NO. 11.

B<sup>3</sup>  
19. (Amended) A vaccine comprising the OMP106 polypeptide of any of claims 1, 2, or 5.

B<sup>4</sup>  
21. (Amended) An antigenic composition comprising the OMP106 polypeptide of any of claims 1, 2, or 5.

B<sup>5</sup>  
27. (Amended) A method of producing an immune response in an animal comprising immunizing the animal with an effective amount of the OMP106 polypeptide of any of claims 1, 2 or 5.

B<sup>6</sup>  
34. (Amended) An isolated or substantially pure OMP106 polypeptide comprising a sequence of SEQ ID NO. 10.

B<sup>7</sup>  
40. (Amended) A method of producing an immune response in an animal comprising immunizing an animal with an effective amount of the OMP106 polypeptide of claim 34.

Please add new claims 42-56 as follows:

42. (New) A vaccine comprising the OMP106 polypeptide of any one of claims 1-6.
43. (New) A vaccine comprising the OMP106 polypeptide of any one of claims 7, 8, 11 or 12.
44. (New) An antigenic composition comprising the OMP106 polypeptide of any one of claims 1-6 and a pharmaceutically acceptable carrier.
45. (New) An antigenic composition comprising the OMP106 polypeptide of any one of claims 7, 8, 11 or 12 and a pharmaceutically acceptable carrier.
46. (New) A vaccine comprising the OMP106 polypeptide of any one of claims 1-6 and an adjuvant.
47. (New) A vaccine comprising the OMP106 polypeptide of any one of claims 7, 8, 11 or 12 and an adjuvant.
48. (New) A vaccine comprising the OMP106 polypeptide of claim 34.
49. (New) A vaccine comprising the OMP106 polypeptide of claim 34 and an adjuvant.
50. (New) An antigenic composition comprising the OMP106 polypeptide of Claim 34.
51. (New) An antigenic composition comprising the OMP106 polypeptide of Claim 34 and a pharmaceutically acceptable carrier.
52. (New) The OMP106 polypeptide of claim 1, which specifically binds an antibody that specifically binds the sequence of SEQ ID NO. 10.
53. (New) An antigenic composition comprising the OMP106 polypeptide of claim 52.
54. (New) An antigenic composition comprising the OMP106 polypeptide of claim 52 and a pharmaceutically acceptable carrier.